预约演示
Fierce Pharma Asia—Eisai eyes Leqembi surge; Takeda nabs Alzheimer's drug option; BIOSECURE Act advances
疫苗临床3期并购上市批准临床2期
Eisai's bullish Leqembi sales projection, Takeda's Alzheimer's licensing deal and the latest on the BIOSECURE Act made our news this week.
Eisaiwing a reportedly bullish assessment Takedaedicare, Eisai has projected a significant sales increase for Leqembi. Takeda paid $100 million upfront for an option to license an anti-amyloid vaccine from AC Immune. The House Oversight Committee voted overwhelmingly to advance a tweaked version of the BIOSECURE Act. And more.
Eisai expects LeqembEisaies foBiogen2024 fiscal year will reach 56.5 billion JapaneLeqembi($364 million), compared with 4.26 billion Japanese yen ($27 million) during the 2023 fiscal year that ended in March. The company believes it and partner Biogen have improved Alzheimer’s disease diagnosis and treatment infrastructure in the U.S. and Japan. Meanwhile, after a short delay, the two companies have started a rolling FDA submission for a subcutaneous version of the anti-amyloid antibody that can be dosed at home.
Eisaikeda paysLeqembiune $100M upfront for Alzheimer's drug as phase 2 readout nearsBiogenAlzheimer’s diseaseanti-amyloid antibody
FelTakedapaneseAC Immuner Takeda is also making a bet on Alzheimer’s disease, paying $100 million upfront for AC Immune’s anti-amyloid beta vaccines. One candidate in the deal, coded ACI-24.060, is in a phase 1b/2 trial in patients with prodromal Alzheimer’s or Down syndrome. The option exercise fee and milestone payments could add up to $2.1 billion.
3. House's updated biosecurity bill sets 2032 decoupling Alzheimer’s diseasery's work with WuXi AppTec, WuXi BAC Immuneamyloid beta vaccinesamyloid betaACI-24.060
In new letter to Defense Department, WuXi AppTec refutes claim of secret data transferWuXi AppTecWuXi Biologics
The House Committee on Oversight and WuXi AppTecity voted overwhelmingly to advance the BIOSECURE Act for a full House vote, Reuters reports. The updated version of the bill would give biopharma companies until Jan. 1, 2032, to end their existing contracts with WuXi AppTec and WuXi Biologics plus three gene sequencing firms targeted in the legislation. For potential new targets of the bill, companies would have five years to cut ties with them. Meanwhile, WuXi AppTec is also defending itself against a claim that it shared a U.S. client’s data with Beijing without consent.
4. After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150MWuXi AppTecWuXi BiologicsWuXi AppTec
Five months after theSanofiFederalShionogiommission derailPompe diseaseroposal to acquire Maze Therapeutics’ Pompe disease program, Shionogi has picked up the asset for $150 million upfront and undisclosed milestones. The candidate, MZE001, is a GYS1 inhibitor designed to stop the toxic buildup of glycogen. It has the potential to become the first oral treatment for Pompe.
5. Shionogi's antiviraU.S.mes up short in global COVID-19 triSanofiMaze TherapeuticsPompe diseaseShionogiMZE001GYS1
ShiShionogiso suffered a setback this week. Its oCOVID-19y protease inhibitor ensitrelvir, which is approved in Japan under the brand name Xocova, failed to significantly beat placebo in reducing the time to sustained resolution of 15 common COVID-19 symptoms in a global phase 3 trial. Despite the primary endpoint miss, Shionogi noted a significant difference in the time to resolution of six COVID symptoms.
Shionogiui licenses GLP-1 portfolio to $400M biotech startuprotease inhibitorprotease by Bain, AensitrelvirChinese)XocovaCOVID-19Shionogi
A nHengrui1 player has emerged with $400 million funding from Bain CapiBain RTW Investments, Atlas Venture and Lyra Capital plus a portfolio of three cardiometabolic candidates from Jiangsu Hengrui Pharma. Hengrui out-licensed the meds for $110 million in upfront and near-term payments, plus a 19.9% stake in the startup, called Hercules. One of the candidates is a dual GLP-1/GIP receptor agonist, the same mechanism as Eli Lilly’s tirzepatide.
7. Under FDA scrutiny, Aurobindo's Eugia tallies a 5th Form 483 in less than a year
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。